CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: RPL14 (ImmuneEditome ID:9045)

1. Gene summary of enriched editing regions for RPL14

check button Gene summary
Gene informationGene symbol

RPL14

Gene ID

9045

GeneSynonymsCAG-ISL-7|CTG-B33|L14|RL14|eL14|hRL14
GeneCytomap

3p22.1

GeneTypeprotein-coding
GeneDescription60S ribosomal protein L14|large ribosomal subunit protein eL14
GeneModificationdate20230409
UniprotIDP50914;F8WDZ7;E7EPB3
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr3:40462514-40464339:+ENST00000338970.9ENSG00000188846.12RPL14UTR3AluSx3,AluSx,Tigger4b,AluYk4chr3:40462514-40464339:+.alignment
chr3:40465868-40466543:+ENST00000338970.9ENSG00000188846.12RPL14UTR3AluSx,AluSg7chr3:40465868-40466543:+.alignment


Top

2. Tumor-specific enriched editing regions for RPL14


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr3:40465868-40466543:+BRCAEER8.4278e-08image
ENSG00000188846.12,RPL14BRCAEAG4.5450e-03image
chr3:40465868-40466543:+HNSCEER5.5724e-05image
ENSG00000188846.12,RPL14HNSCEAG4.6928e-04image
chr3:40465868-40466543:+UCECEER1.4351e-02image
ENSG00000188846.12,RPL14UCECEAG1.2437e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr3:40465868-40466543:+THCAPathEER2.6925e-025.4018e-030.1267image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr3:40465868-40466543:+ESCAEER1.6781e-023.5913e-021.9474e+01image

Top

3. Enriched editing regions and immune related genes for RPL14


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr3:40465868-40466543:+PCPGEERENSG00000149260,CAPN50.41262.3318e-052.5002e-080.4092imageNDKC1;EIF4A3NAEosinophilsGSVA_HALLMARK_MITOTIC_SPINDLE
chr3:40465868-40466543:+PCPGEERENSG00000075945,KIFAP30.39386.7423e-051.1624e-090.4430imageNDKC1;EIF4A3;TIA1KIFAP3Dendritic_cells_restingGSVA_HALLMARK_PROTEIN_SECRETION
chr3:40465868-40466543:+PCPGEERENSG00000160349,LCN10.32171.0915e-036.9033e-100.4484imageNDKC1NADendritic_cells_restingGSVA_HALLMARK_KRAS_SIGNALING_DN
chr3:40465868-40466543:+PCPGEERENSG00000006128,TAC10.24133.1890e-025.2250e-100.4512imageNNTAC1Plasma_cells
chr3:40465868-40466543:+PCPGEERENSG00000168032,ENTPD30.24343.3795e-021.9245e-080.4122imageNDKC1;EIF4A3;TIA1ENTPD3Plasma_cellsGSVA_HALLMARK_PROTEIN_SECRETION
chr3:40465868-40466543:+UVMEERENSG00000124523,SIRT5-0.48514.2008e-031.3803e-04-0.4554imageNDKC1;EIF4A3;TIA1NANeutrophilsGSVA_HALLMARK_KRAS_SIGNALING_DN
chr3:40465868-40466543:+UVMEERENSG00000188493,C19orf540.48734.7101e-035.2547e-090.6483imageNDKC1;EIF4A3;TIA1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYOGENESIS
chr3:40465868-40466543:+UVMEERENSG00000188807,TMEM2010.48485.3677e-037.6020e-060.5236imageNDKC1;EIF4A3;TIA1NAMacrophages_M2GSVA_HALLMARK_KRAS_SIGNALING_DN
chr3:40465868-40466543:+UVMEERENSG00000171603,CLSTN10.47415.4614e-032.4339e-040.4402imageNDKC1;EIF4A3;TIA1CLSTN1T_cells_regulatory_(Tregs)GSVA_HALLMARK_APICAL_JUNCTION
chr3:40465868-40466543:+UVMEERENSG00000204305,AGER-0.47845.8462e-035.9226e-04-0.4148imageNDKC1;EIF4A3;TIA1AGERT_cells_CD4_memory_restingGSVA_HALLMARK_UV_RESPONSE_UP

More results



Top

4. Enriched editing regions and immune related splicing for RPL14


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr3:40462514-40464339:+
GBMEERA5ENSG00000131943.13chr1929708253:29708423:29715124:29715221:29714906:29715221-0.42156.4726e-042.5010e-07-0.4740imageNADAR;FBL;IGF2BP2NAMonocytesGSVA_HALLMARK_MYC_TARGETS_V1
ENSG00000188846.12,RPL14
KIRPEAGIRENSG00000258130.3chr1630204315:30204686:30204826:30204890-0.22362.0410e-021.5806e-07-0.4013imageNADAR;EIF4A3;U2AF2NADendritic_cells_activatedGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000188846.12,RPL14
KIRPEAGIRENSG00000134030.9chr1848859881:48861292:48862008:48862355-0.18261.5387e-023.5346e-14-0.4958imageNADAR;ALYREF;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS2;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM27;RBM5;SF3A3;SF3B4;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1NAB_cells_naiveGSVA_HALLMARK_P53_PATHWAY
chr3:40465868-40466543:+
OVEERESENSG00000168389.13chr139966661:39966691:39966810:39967169:39967627:39967711-0.20677.4740e-039.4000e-10-0.4613imageNDKC1;EIF4A3;TIA1NAT_cells_CD4_memory_restingGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr3:40465868-40466543:+
TGCTEERESENSG00000146909.3chr7156954111:156954298:156958605:156958856:156959850:1569599730.33235.2259e-031.5210e-060.4163imageNDKC1;EIF4A3;TIA1NAB_cells_naiveGSVA_HALLMARK_NOTCH_SIGNALING
ENSG00000188846.12,RPL14
TGCTEAGESENSG00000011426.6chr736415757:36415884:36417079:36417190:36419243:364194670.46695.7624e-061.5164e-070.4556imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL14;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZC3H7B;ZNF184ANLNMacrophages_M2GSVA_HALLMARK_TGF_BETA_SIGNALING
ENSG00000188846.12,RPL14
TGCTEAGIRENSG00000145020.10chr349421491:49422049:49422360:49422451-0.31662.2063e-034.2670e-06-0.4298imageNAIFM1;AUH;BCCIP;BUD13;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28B;LSM11;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;VIM;XRN2;ZNF184NAMacrophages_M2GSVA_HALLMARK_ANGIOGENESIS
ENSG00000188846.12,RPL14
TGCTEAGIRENSG00000137200.8chr637475320:37475916:37476125:37476194-0.36975.5313e-047.2356e-06-0.4064imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZNF184NAMacrophages_M2GSVA_HALLMARK_ANGIOGENESIS
chr3:40465868-40466543:+
TGCTEERIRENSG00000005436.9chr275662705:75670284:75671949:75672016-0.49381.2995e-052.3388e-07-0.4364imageNDKC1;EIF4A3;TIA1NAMacrophages_M2GSVA_HALLMARK_ANGIOGENESIS
ENSG00000188846.12,RPL14
TGCTEAGMEXENSG00000119185.8chr29418625:9418732:9420034:9420100:9422478:9422696:9423372:94234800.31144.8125e-031.5065e-060.4596imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZC3H7B;ZNF184ITGB1BP1Macrophages_M2GSVA_HALLMARK_ANGIOGENESIS

More results



Top

5. Enriched editing regions and immune infiltration for RPL14


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr3:40465868-40466543:+ACCEERT_cells_regulatory_(Tregs)3.4596e-02-0.2966image
chr3:40462514-40464339:+BLCAEERMast_cells_resting2.4988e-030.3534image
chr3:40465868-40466543:+BLCAEERMacrophages_M17.3519e-040.2428image
ENSG00000188846.12,RPL14BLCAEAGMacrophages_M11.7484e-030.2222image
chr3:40465868-40466543:+BRCAEERMacrophages_M14.0908e-030.0960image
ENSG00000188846.12,RPL14BRCAEAGMacrophages_M15.6592e-030.0912image
chr3:40465868-40466543:+COADEERB_cells_memory1.8243e-030.2594image
ENSG00000188846.12,RPL14COADEAGB_cells_memory1.4266e-020.1928image
chr3:40465868-40466543:+DLBCEERT_cells_regulatory_(Tregs)4.9591e-020.3500image
ENSG00000188846.12,RPL14DLBCEAGT_cells_regulatory_(Tregs)1.0182e-030.5385image
ENSG00000188846.12,RPL14ESCAEAGDendritic_cells_resting2.3588e-030.2665image
chr3:40462514-40464339:+GBMEERMacrophages_M21.8456e-020.2140image
chr3:40465868-40466543:+GBMEERMonocytes7.8631e-040.2721image
ENSG00000188846.12,RPL14GBMEAGDendritic_cells_resting3.6625e-040.2863image
chr3:40465868-40466543:+HNSCEERT_cells_CD4_memory_activated7.5642e-030.2024image
ENSG00000188846.12,RPL14HNSCEAGT_cells_CD4_memory_activated3.2954e-020.1552image
chr3:40465868-40466543:+KICHEERT_cells_follicular_helper1.5065e-020.3967image
ENSG00000188846.12,RPL14KICHEAGT_cells_follicular_helper1.0617e-020.3949image
chr3:40462514-40464339:+KIRCEERT_cells_CD4_memory_activated5.6348e-03-0.2280image
chr3:40465868-40466543:+KIRCEERT_cells_gamma_delta7.1078e-030.1641image
ENSG00000188846.12,RPL14KIRCEAGPlasma_cells2.5327e-020.1339image
chr3:40462514-40464339:+KIRPEERMonocytes2.7600e-02-0.2419image
chr3:40465868-40466543:+KIRPEERMast_cells_activated3.1029e-030.2086image
ENSG00000188846.12,RPL14KIRPEAGNK_cells_resting1.1378e-020.1760image
ENSG00000188846.12,RPL14LAMLEAGB_cells_memory1.5306e-020.2495image
chr3:40465868-40466543:+LGGEERMacrophages_M07.5341e-04-0.1463image
ENSG00000188846.12,RPL14LGGEAGMonocytes5.6717e-040.1497image
chr3:40465868-40466543:+LIHCEERMacrophages_M08.6176e-03-0.1921image
ENSG00000188846.12,RPL14LIHCEAGMonocytes1.9009e-020.1709image
chr3:40462514-40464339:+LUSCEERMast_cells_activated1.1842e-030.3722image
chr3:40465868-40466543:+LUSCEERT_cells_CD86.6362e-040.2448image
ENSG00000188846.12,RPL14LUSCEAGT_cells_CD82.7576e-020.1570image
chr3:40465868-40466543:+MESOEERMacrophages_M22.5462e-020.2792image
chr3:40465868-40466543:+OVEERT_cells_CD4_memory_activated3.2572e-040.2440image
ENSG00000188846.12,RPL14OVEAGT_cells_CD4_memory_activated2.4778e-040.2415image
chr3:40465868-40466543:+PAADEERT_cells_CD4_memory_activated4.6292e-02-0.1968image
chr3:40465868-40466543:+PCPGEERDendritic_cells_resting1.4401e-020.1863image
ENSG00000188846.12,RPL14PCPGEAGDendritic_cells_resting7.9396e-030.2018image
chr3:40465868-40466543:+PRADEERT_cells_CD4_memory_resting1.4958e-020.1104image
ENSG00000188846.12,RPL14PRADEAGT_cells_CD4_memory_resting3.7800e-030.1311image
ENSG00000188846.12,RPL14READEAGMonocytes4.8376e-02-0.2458image
chr3:40462514-40464339:+SARCEERDendritic_cells_resting3.3959e-020.2092image
chr3:40462514-40464339:+SKCMEERT_cells_CD84.5860e-030.1875image
chr3:40465868-40466543:+SKCMEERPlasma_cells3.2199e-030.1610image
ENSG00000188846.12,RPL14SKCMEAGT_cells_CD81.5011e-030.1691image
chr3:40462514-40464339:+STADEERT_cells_CD4_memory_activated1.7097e-02-0.1621image
chr3:40465868-40466543:+STADEERB_cells_memory1.5377e-02-0.1621image
ENSG00000188846.12,RPL14STADEAGB_cells_memory4.9591e-02-0.1181image
chr3:40465868-40466543:+TGCTEERT_cells_CD81.0314e-030.2857image
ENSG00000188846.12,RPL14TGCTEAGT_cells_CD81.3378e-030.2784image
chr3:40462514-40464339:+THCAEERT_cells_CD4_memory_resting2.3236e-050.2300image
chr3:40465868-40466543:+THCAEERT_cells_regulatory_(Tregs)1.2191e-020.1141image
ENSG00000188846.12,RPL14THCAEAGMacrophages_M12.2895e-02-0.1034image
chr3:40462514-40464339:+THYMEERDendritic_cells_activated1.8000e-02-0.4034image
chr3:40465868-40466543:+THYMEERT_cells_CD4_naive2.6099e-03-0.2979image
ENSG00000188846.12,RPL14THYMEAGT_cells_CD4_naive8.0266e-03-0.2637image
chr3:40465868-40466543:+UCECEERPlasma_cells4.7601e-020.1868image
chr3:40462514-40464339:+UCSEERNK_cells_resting9.7462e-030.5272image
chr3:40462514-40464339:+UVMEERMonocytes9.1878e-03-0.4465image
chr3:40465868-40466543:+UVMEERT_cells_regulatory_(Tregs)7.2547e-030.3300image
ENSG00000188846.12,RPL14UVMEAGT_cells_regulatory_(Tregs)8.5933e-030.3234image


Top

6. Enriched editing regions and immune gene sets for RPL14


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000188846.12,RPL14ACCGSVA_HALLMARK_G2M_CHECKPOINTEAG4.2426e-020.2853image
chr3:40465868-40466543:+ACCGSVA_HALLMARK_E2F_TARGETSEER1.5605e-020.3370image
ENSG00000188846.12,RPL14BLCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG5.1703e-040.2457image
chr3:40462514-40464339:+BLCAGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER1.8758e-02-0.2783image
chr3:40465868-40466543:+BLCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER1.0498e-040.2777image
chr3:40465868-40466543:+BRCAGSVA_HALLMARK_GLYCOLYSISEER3.3756e-060.1549image
chr3:40462514-40464339:+BRCAGSVA_HALLMARK_G2M_CHECKPOINTEER3.3091e-05-0.1577image
ENSG00000188846.12,RPL14BRCAGSVA_HALLMARK_PROTEIN_SECRETIONEAG3.0022e-070.1680image
ENSG00000188846.12,RPL14CESCGSVA_HALLMARK_SPERMATOGENESISEAG1.6929e-02-0.2023image
chr3:40465868-40466543:+CESCGSVA_HALLMARK_SPERMATOGENESISEER3.0179e-03-0.2534image
ENSG00000188846.12,RPL14CHOLGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG3.7939e-02-0.4669image
ENSG00000188846.12,RPL14COADGSVA_HALLMARK_MYC_TARGETS_V1EAG1.7208e-02-0.1875image
ENSG00000188846.12,RPL14DLBCGSVA_HALLMARK_MYC_TARGETS_V2EAG3.3333e-02-0.3659image
chr3:40465868-40466543:+DLBCGSVA_HALLMARK_MYC_TARGETS_V2EER1.5793e-02-0.4232image
chr3:40462514-40464339:+ESCAGSVA_HALLMARK_PROTEIN_SECRETIONEER4.6573e-02-0.2005image
ENSG00000188846.12,RPL14ESCAGSVA_HALLMARK_APOPTOSISEAG2.2090e-020.2022image
chr3:40465868-40466543:+ESCAGSVA_HALLMARK_APOPTOSISEER1.4308e-030.3045image
ENSG00000188846.12,RPL14GBMGSVA_HALLMARK_HEME_METABOLISMEAG6.4804e-050.3192image
chr3:40465868-40466543:+GBMGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.5274e-040.3053image
chr3:40462514-40464339:+GBMGSVA_HALLMARK_BILE_ACID_METABOLISMEER5.0055e-040.3117image
chr3:40465868-40466543:+HNSCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER9.3902e-040.2493image
ENSG00000188846.12,RPL14HNSCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.2016e-030.2338image
ENSG00000188846.12,RPL14KICHGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG4.3497e-02-0.3169image
chr3:40462514-40464339:+KIRCGSVA_HALLMARK_COMPLEMENTEER4.5274e-02-0.1660image
chr3:40465868-40466543:+KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.1216e-030.1614image
ENSG00000188846.12,RPL14KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.1405e-030.1831image
chr3:40462514-40464339:+KIRPGSVA_HALLMARK_G2M_CHECKPOINTEER1.6088e-02-0.2635image
chr3:40465868-40466543:+LAMLGSVA_HALLMARK_TGF_BETA_SIGNALINGEER3.6229e-030.3928image
chr3:40465868-40466543:+LGGGSVA_HALLMARK_G2M_CHECKPOINTEER1.9414e-11-0.2868image
ENSG00000188846.12,RPL14LGGGSVA_HALLMARK_MYC_TARGETS_V2EAG2.9162e-15-0.3347image
ENSG00000188846.12,RPL14LIHCGSVA_HALLMARK_MYC_TARGETS_V2EAG1.5696e-03-0.2290image
chr3:40465868-40466543:+LIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEER9.2405e-030.1904image
chr3:40462514-40464339:+LUSCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER3.3309e-020.2495image
ENSG00000188846.12,RPL14MESOGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG1.9252e-02-0.2919image
chr3:40465868-40466543:+MESOGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER1.7861e-02-0.2952image
chr3:40462514-40464339:+OVGSVA_HALLMARK_PROTEIN_SECRETIONEER9.5838e-030.2145image
chr3:40465868-40466543:+OVGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER5.8406e-060.3049image
ENSG00000188846.12,RPL14OVGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.8564e-070.3384image
chr3:40462514-40464339:+PAADGSVA_HALLMARK_SPERMATOGENESISEER8.0988e-03-0.3858image
chr3:40465868-40466543:+PAADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER4.3206e-020.1996image
ENSG00000188846.12,RPL14PCPGGSVA_HALLMARK_PROTEIN_SECRETIONEAG7.1211e-040.2557image
chr3:40465868-40466543:+PCPGGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER9.2307e-04-0.2504image
ENSG00000188846.12,RPL14PRADGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG6.4166e-050.1803image
chr3:40465868-40466543:+PRADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.7731e-030.1279image
ENSG00000188846.12,RPL14READGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG1.4810e-020.3011image
chr3:40462514-40464339:+SARCGSVA_HALLMARK_MYC_TARGETS_V2EER2.3930e-03-0.2961image
chr3:40465868-40466543:+SARCGSVA_HALLMARK_NOTCH_SIGNALINGEER1.5261e-02-0.1676image
ENSG00000188846.12,RPL14SARCGSVA_HALLMARK_NOTCH_SIGNALINGEAG8.9135e-03-0.1796image
chr3:40465868-40466543:+SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER9.0960e-060.2405image
ENSG00000188846.12,RPL14SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.3588e-040.1954image
chr3:40462514-40464339:+SKCMGSVA_HALLMARK_MYC_TARGETS_V2EER1.3967e-02-0.1630image
chr3:40462514-40464339:+STADGSVA_HALLMARK_BILE_ACID_METABOLISMEER6.9180e-030.1833image
ENSG00000188846.12,RPL14STADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG3.3322e-050.2466image
chr3:40465868-40466543:+STADGSVA_HALLMARK_HYPOXIAEER2.7946e-030.1993image
chr3:40465868-40466543:+TGCTGSVA_HALLMARK_ANGIOGENESISEER5.3895e-05-0.3478image
ENSG00000188846.12,RPL14TGCTGSVA_HALLMARK_ANGIOGENESISEAG7.0472e-05-0.3414image
chr3:40462514-40464339:+THCAGSVA_HALLMARK_MYC_TARGETS_V1EER4.4017e-04-0.1918image
chr3:40465868-40466543:+THCAGSVA_HALLMARK_ANDROGEN_RESPONSEEER8.3193e-080.2412image
ENSG00000188846.12,RPL14THCAGSVA_HALLMARK_ANDROGEN_RESPONSEEAG8.6717e-100.2741image
ENSG00000188846.12,RPL14THYMGSVA_HALLMARK_DNA_REPAIREAG8.8435e-03-0.2605image
chr3:40462514-40464339:+THYMGSVA_HALLMARK_ANGIOGENESISEER5.1652e-03-0.4688image
ENSG00000188846.12,RPL14UCECGSVA_HALLMARK_BILE_ACID_METABOLISMEAG2.0827e-020.2144image
chr3:40465868-40466543:+UCECGSVA_HALLMARK_ADIPOGENESISEER4.8831e-030.2630image
chr3:40465868-40466543:+UCSGSVA_HALLMARK_APICAL_JUNCTIONEER6.4063e-030.4141image
ENSG00000188846.12,RPL14UCSGSVA_HALLMARK_APICAL_JUNCTIONEAG7.0709e-030.4049image
ENSG00000188846.12,RPL14UVMGSVA_HALLMARK_MYOGENESISEAG1.1075e-030.3956image
chr3:40462514-40464339:+UVMGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER3.6556e-020.3653image
chr3:40465868-40466543:+UVMGSVA_HALLMARK_MYOGENESISEER1.0737e-030.3966image


Top

7. Enriched editing regions and drugs for RPL14


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000188846.12,RPL14ACCCGP.60474EAG1.0267e-02-0.3564image
chr3:40465868-40466543:+ACCCGP.60474EER3.4086e-03-0.4025image
chr3:40465868-40466543:+BLCAAxitinibEER5.1262e-040.2497image
chr3:40462514-40464339:+BLCABX.795EER8.7809e-040.3862image
ENSG00000188846.12,RPL14BLCAAxitinibEAG1.6719e-030.2231image
chr3:40462514-40464339:+BRCABryostatin.1EER1.1250e-02-0.0967image
chr3:40465868-40466543:+BRCAAxitinibEER6.5149e-040.1140image
ENSG00000188846.12,RPL14BRCAGW843682XEAG5.2903e-040.1141image
ENSG00000188846.12,RPL14CESCJW.7.52.1EAG2.2884e-02-0.1929image
chr3:40465868-40466543:+CESCJW.7.52.1EER4.7790e-03-0.2415image
ENSG00000188846.12,RPL14CHOLAKT.inhibitor.VIIIEAG1.9720e-03-0.6487image
ENSG00000188846.12,RPL14COADDocetaxelEAG1.0892e-050.3390image
chr3:40465868-40466543:+COADDocetaxelEER2.8980e-050.3432image
chr3:40465868-40466543:+DLBCDasatinibEER6.6541e-03-0.4699image
ENSG00000188846.12,RPL14DLBCDoxorubicinEAG3.0443e-020.3717image
ENSG00000188846.12,RPL14ESCAEHT.1864EAG1.4430e-020.2158image
chr3:40462514-40464339:+ESCALenalidomideEER6.8903e-03-0.2699image
chr3:40465868-40466543:+ESCAEHT.1864EER4.9622e-030.2697image
chr3:40462514-40464339:+GBMDMOGEER1.9450e-03-0.2790image
ENSG00000188846.12,RPL14GBMDMOGEAG3.6152e-05-0.3295image
chr3:40465868-40466543:+GBMBI.D1870EER1.3255e-050.3485image
ENSG00000188846.12,RPL14HNSCMethotrexateEAG1.1938e-02-0.1840image
chr3:40465868-40466543:+HNSCCisplatinEER3.9113e-03-0.2183image
chr3:40462514-40464339:+HNSCEHT.1864EER3.1417e-020.2283image
chr3:40465868-40466543:+KICHBosutinibEER2.5954e-02-0.3659image
ENSG00000188846.12,RPL14KICHBosutinibEAG6.5543e-03-0.4179image
chr3:40465868-40466543:+KIRCBMS.708163EER2.1091e-02-0.1408image
chr3:40462514-40464339:+KIRCGefitinibEER6.4856e-03-0.2251image
ENSG00000188846.12,RPL14KIRCBMS.708163EAG1.0904e-02-0.1522image
chr3:40462514-40464339:+KIRPBicalutamideEER1.2971e-03-0.3473image
ENSG00000188846.12,RPL14KIRPAZD6244EAG1.2614e-030.2232image
chr3:40465868-40466543:+KIRPAZD6244EER9.2075e-030.1842image
ENSG00000188846.12,RPL14LAMLAZD6482EAG4.4976e-03-0.2906image
chr3:40465868-40466543:+LAMLAG.014699EER5.6702e-030.3750image
chr3:40465868-40466543:+LGGBAY.61.3606EER5.8003e-120.2939image
ENSG00000188846.12,RPL14LGGCI.1040EAG7.5188e-140.3180image
ENSG00000188846.12,RPL14LIHCBexaroteneEAG8.2282e-050.2832image
chr3:40465868-40466543:+LIHCBexaroteneEER1.3857e-030.2328image
chr3:40465868-40466543:+LUSCBX.795EER2.7294e-030.2162image
chr3:40462514-40464339:+LUSCErlotinibEER6.6436e-030.3150image
chr3:40465868-40466543:+MESOA.770041EER3.2421e-03-0.3625image
ENSG00000188846.12,RPL14MESOA.770041EAG8.4141e-03-0.3267image
chr3:40462514-40464339:+OVJW.7.52.1EER4.2284e-03-0.2362image
chr3:40465868-40466543:+OVAZD6244EER2.0436e-05-0.2874image
ENSG00000188846.12,RPL14OVEtoposideEAG4.1022e-040.2331image
chr3:40465868-40466543:+PCPGMidostaurinEER4.2675e-060.3424image
ENSG00000188846.12,RPL14PCPGMidostaurinEAG5.1447e-060.3397image
chr3:40465868-40466543:+PRADAZD.2281EER1.2707e-02-0.1133image
ENSG00000188846.12,RPL14PRADBMS.509744EAG6.5063e-040.1541image
ENSG00000188846.12,RPL14READAS601245EAG3.5942e-03-0.3561image
chr3:40465868-40466543:+SARCAxitinibEER4.4281e-040.2409image
chr3:40462514-40464339:+SARCGSK.650394EER9.8836e-040.3199image
ENSG00000188846.12,RPL14SARCCytarabineEAG1.5401e-040.2576image
ENSG00000188846.12,RPL14SKCMCytarabineEAG1.0408e-020.1368image
chr3:40465868-40466543:+SKCMJW.7.52.1EER2.1435e-02-0.1260image
chr3:40462514-40464339:+SKCMAxitinibEER6.9976e-030.1785image
ENSG00000188846.12,RPL14STADA.443654EAG8.7418e-030.1573image
chr3:40465868-40466543:+STADBexaroteneEER1.4760e-02-0.1631image
chr3:40462514-40464339:+STADJNJ.26854165EER4.3597e-03-0.1937image
chr3:40462514-40464339:+TGCTEtoposideEER1.0690e-020.3033image
ENSG00000188846.12,RPL14TGCTBosutinibEAG2.4379e-04-0.3165image
chr3:40465868-40466543:+TGCTBosutinibEER2.3377e-05-0.3632image
chr3:40465868-40466543:+THCABMS.708163EER4.2591e-06-0.2077image
ENSG00000188846.12,RPL14THCABMS.708163EAG1.3180e-09-0.2712image
chr3:40462514-40464339:+THCAFH535EER7.5997e-040.1839image
chr3:40462514-40464339:+THYMDMOGEER3.6889e-05-0.6460image
ENSG00000188846.12,RPL14THYMCMKEAG9.5748e-050.3801image
chr3:40465868-40466543:+THYMCMKEER1.6834e-030.3102image
chr3:40462514-40464339:+UCECAZD7762EER1.4539e-030.4757image
chr3:40465868-40466543:+UCECDMOGEER2.4977e-040.3381image
ENSG00000188846.12,RPL14UCECMetforminEAG5.2839e-03-0.2574image
chr3:40465868-40466543:+UCSBortezomibEER5.3871e-03-0.4219image
chr3:40462514-40464339:+UCSMethotrexateEER3.0868e-02-0.4508image
ENSG00000188846.12,RPL14UCSBortezomibEAG1.3112e-02-0.3754image
ENSG00000188846.12,RPL14UVMBMS.708163EAG3.2254e-030.3600image
chr3:40462514-40464339:+UVMAMG.706EER3.6828e-02-0.3648image
chr3:40465868-40466543:+UVMBMS.708163EER3.2937e-030.3592image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType
chr3:40462514-40464339:+ENST00000338970.9P50914DB11638ArtenimolSmallMoleculeDrug
chr3:40465868-40466543:+ENST00000338970.9P50914DB11638ArtenimolSmallMoleculeDrug